About speakers
Dr. Kizzmekia Corbett, Lead Scientist, COVID-19 mRNA vaccine development; Assistant Professor, Harvard TH Chan School of Public Health
Kizzmekia Corbett is the chief scientist of the coronavirus research group of the Center for Vaccines Research at the US National Institutes of Health, where she studies coronavirus biology and vaccine development. . Those six years of research led to the groundbreaking discovery that a stable version of the spike protein, found on the surface of all coronaviruses, would be a prime target for vaccines, methods treatment and diagnosis. At the start of the COVID-19 pandemic, she and her colleagues were at the heart of the development of the Moderna mRNA vaccine and the therapeutic monoclonal antibody Eli Lilly, both of which entered clinical trials for the first time. ready in the world. As a result, her work is having a significant impact on ending the worst respiratory disease pandemic in more than 100 years. Corbett is currently an assistant professor in the Department of Immunology and Infectious Diseases at the Harvard TH Chan School of Public Health, an Assistant Professor of Shutzer at Harvard’s Radcliffe Institute for Advanced Study, and an associate fellow by Phillip T. and the Susan M. Ragon Institute. Her work has now extended beyond the rapid development of a COVID-19 vaccine to the prospect of this and future viral pandemics.
Perhaps as important as his scientific achievements, Dr. Corbett has appeared in public as the face of a diverse and rising generation of talented scientists who will change the world. She is an excellent science communicator, explaining vaccines and viruses in ways that are accessible to the media, two US presidents, and a global audience.
Laurent Duvernay-Tardif, Graduate in Medicine; Super Cup Champion
Called “the coolest man in the NFL,” Laurent Duvernay-Tardif is an 8-year NFL veteran, Super Bowl champion, and the only active NFL player with a medical degree. Just months after his Super Bowl win with the Kansas City Chiefs – and in the midst of the COVID-19 pandemic – Duvernay-Tardif has stepped away from football to join the medical frontline. From the incredible heights of winning a SuperBowl to the burnout of orderly work, Duvernay-Tardif shares her remarkable personal story, talking about resilience, leadership, and more.
As plans for the 2020 NFL season intensified, Duvernay-Tardif stepped down from the game he loved, becoming the first player of the 2020 NFL season to publicly decline. For the first time in his remarkable career, Duvernay-Tardif couldn’t reconcile his twin passions for football and medicine, and with the team’s Super Bowl championship just a few months behind him, he found himself is on the front lines of the pandemic, working in a long-term care facility in Quebec. While working on the front lines, Duvernay-Tardif enrolled in Harvard’s TH Chan School of Public Health.
Juergen Eckhardt, SVP and Team Leader, Leaps by Bayer
Juergen Eckhardt is SVP and Head of Leaps by Bayer, Bayer’s impact investing unit. Leaps’ mission is to invest in disruptive technologies and disruptive business models in healthcare and agriculture. Juergen has been a venture capitalist since 2002 and currently serves on the boards of Joyn Bio, Dewpoint, Century, Khloris, Oerth Bio, Immunitas, eGenesis and others. Previously, Juergen was a management consultant and Associate Partner of McKinsey & Co. and a member of the McKinsey Healthcare Leadership Team. He began his career as a radiologist at the University Hospital Basel, Switzerland. Juergen received an MD from the University of Basel and an MBA from INSEAD in Fontainebleau, France.
Elizabeth Bramson-Boudreau, CEO and Publisher, MIT Technology Review
Elizabeth Bramson-Boudreau is the CEO and publisher of MIT Technology Review, the independent media arm of the Massachusetts Institute of Technology.
Since Elizabeth took the helm of MIT Technology Review in mid-2017, the business has undergone a major transition from its former position as a respected print magazine but dedicated to a media brand. Widely read cross-platform with a global audience and a sustainable business. . Under her leadership, MIT Technology Review has been praised for its editorial authority, best-in-class facts, and novel use of original, independent research to assist both advertisers and publishers. fake.
Elizabeth has 20 years of experience building and running teams at the world’s top media companies. She maintains a keen focus on new ways to commercialize media content to appeal to demanding, demanding consumers as well as B2B audiences.
Prior to joining MIT Technology Review, Elizabeth held a senior executive role at The Economist Group, where her leadership roles spanned business sectors and included mergers and acquisitions; editorial and product creation and modernization; the sale; marketing; and events. Earlier in her career, she worked as a consultant advising technology companies on market penetration and international expansion.
Elizabeth holds an executive MBA from the London Business School, a Master’s degree from the London School of Economics and a bachelor’s degree from Swarthmore College.
